Best of Myeloma Highlights, Debates, Discussions!! ➡️Really excited about this stellar line up of Myeloma experts at 2nd Annual Kyle Barlogie Symposium in MN ➡️A little nervous about debating against transplant.. #MedTwitter #MMSM #MayoClinic #msk

Presented at #IMS25, now in Blood Journals Portfolio 👉22% of NDMM HR by new IMWG Consensus Genomic model 👉CD38 Ab & ASCT had ⬆️⬆️PFS for both SR and HR 👉If no HR genomics, ⬆️ B2M had similar outcomes as normal B2M #MMSM #MedTwitter Anaïs Schavgoulidze 👏👏

Excellent review in NEJM by Vincent Rajkumar and Shaji Kumar ➡️No need for testing for MGUS in asymptomatic with no family hx ➡️No need for BMBx and imaging in low risk MGUS ➡️Abnormal light chains and K/L ratio should be adjusted for age and renal function #MMSM #MGUS #MedTwitter

Looking forward to this event. There is still time to register and learn from the giants of Myeloma web.cvent.com/event/3197041a… Summary - 2nd Annual Kyle Barlogie Plasma Cell Disorders Symposium #mmsm #MedTwitter #MedEd Mayo Clinic Memorial Sloan Kettering Cancer Center

➡️40% of pts with LCMM had t11;14. I have historically seen early + deep responses with LCMM and slow + plateaued responses with t11;14. It would be interesting to see if LCMM with t11;14 still has early and deep RR Saurabh Zanwar Rahul Banerjee, MD, FACP #mmsm

A great day here in Minnesota for discussion, debates, and exchange of knowledge, ideas, and opinions at the 2nd Annual Kyle Barlogie #PlasmaCellDisorders symposium. #MMSM MSK Department of Medicine Mayo Clinic #MedTwitter #MedEd

NDMM diagnostics and Risk Assessment : Great talk by Luciano J Costa on MRD driven treatment adaptations in Multiple Myeloma Kyle Barlogie Plasma Cell Disorders Symposium #MMSM #MedTwitter

1/ Thanks Larry (and all co-authors) and AmericanJournalofHematology for this! RW data for a frequent q in my own #MMsm clinic, namely patients starting teclistamab disappointed by D30 results after hearing "Median time to 1st response 1.1 mo"... Can we predict delayed response conversion?

MRD vs No MRD guided treatment for Myeloma: A great debate b/w Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 (yes) vs Luciano J Costa (no) and discussion by Vincent Rajkumar on MRD driven treatment in Multiple Myeloma Kyle Barlogie Plasma Cell Disorders Symposium #MMSM #MedTwitter #MedEd #AgreeToAgree

Fantastic event w discussion, debates, & exchange of knowledge, ideas, and opinions at the Kyle Barlogie #PlasmaCellDisorders symposium #MMSM MSK Department of Medicine Mayo Clinic #MedTwitter #MedEd Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 Vincent Rajkumar Shaji Kumar Francesco Maura Urvi Shah Sridevi Rajeeve, MD & many others

➡️CTC-high pts (>0.175%) had ⬇️⬇️ PFS c/w CTC-low pts ➡️CTC-high MRD neg pts🟰 PFS c/w CTC-low MRD+ pts

CIDP as another (rare) MNT-style AE of cilta-cel in #MMsm. Great correlatives in Blood Cancer Journal by 🇩🇪 group: TCRseq identified oligoclonal CARs (CDR epitopes similar to GBS) in one case. Early treatment with high-dose Cy, IT chemo is key - now need preemptive ID & mitigation!

Clinical DNA sequencing of MM tumor samples: Del of chr 4p in anti-CD38 exposed pts were monoallelic, suggesting that haploinsufficiency may be enough to diminish CD38 surface expression and drive resistance to further anti-CD38 therapy

We're in Charleston, SC, for #iwHRMM25! Kicking off an exciting meeting focusing on high-risk #myeloma is Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 of Memorial Sloan Kettering Cancer Center. 🩸 #MMSM #MultipleMyeloma #HemOnc #ImmunoOnc

Hamza Hashmi Not right now. But we retained it as a category with the understanding that we may do something different for that group later on as data emerges. That’s the group I’m most concerned about. We need trials for HR and for double hit HR. The definition of double hit HR group is

I remember this post and patient story from 4 years ago. Therapeutic advances in #MMSM need to be offered to those most in need of them. BelaVd would be a great option for many pts who are unable to receive BsAb and CAR T. #MMSM #MedTwitter #CureMyeloma #UnMetNeed #MedEd

With median fu of 17m, no cases of cerebellar toxicity seen in 18 pts. No major Skin/Oral/Nail toxicities. Efficacy data appears similar to Arlo-cel. N is small but is finding the ✅ dose the trick for avoiding 🧠toxicities for GPRC5d CAR T #MMSM #Myeloma

Debulking before BsAb to⬆️outcomes for #RRMM ➡️n=44,50% EMD,HRCG,⬆️BM Dx ➡️C/w historical cohorts, ⬆️ORR and PFS in EMD ➡️Need to define optimal debulking (⬇️M-Prt, sFLC, PET SUV) and c/w matched control of no prior debulking 10.1038/s41408-025-01365-y #MMSM Blood Cancer Journal